tert-butyl (2-(naphthalen-1-ylamino)ethyl)carbamate | 1401719-08-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: tert-butyl (2-(naphthalen-1-ylamino)ethyl)carbamate
• 英文别名: tert-butyl N-[2-(naphthalen-1-ylamino)ethyl]carbamate
• CAS: 1401719-08-1
• 化学式: C₁₇H₂₂N₂O₂
• 分子量: 286.374
• InChiKey: UYTDZKQDUSTIAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-(naphthalen-1-ylamino)ethyl)carbamate 在 potassium tert-butylate 作用下， 以 1,4-二氧六环 为溶剂， 生成 1-Naphthyl-(1)-imidazolidinon-(2)
  参考文献：
  名称：

  碱促进合成 3,4-二氢-2(1H)-喹唑啉酮

  摘要：

  开发了一种方便、简洁的碱促进合成 3,4-二氢-2(1H)-喹唑啉酮和多元环脲的方法。在 tBuOK 存在下，多种 3,4-二氢-2(1H)-喹唑啉酮以及 N-芳基化五元、六元和九元环脲在温和条件下很容易合成。该方法为环脲提供了一种替代合成工具包。

  DOI：

  10.1515/znb-2024-0045
• 作为产物：
  描述：

  N-叔丁氧羰基-1,2-乙二胺 、 1-氟萘 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 1,4-二氧六环 为溶剂， 生成 tert-butyl (2-(naphthalen-1-ylamino)ethyl)carbamate
  参考文献：
  名称：

  碱促进合成 3,4-二氢-2(1H)-喹唑啉酮

  摘要：

  开发了一种方便、简洁的碱促进合成 3,4-二氢-2(1H)-喹唑啉酮和多元环脲的方法。在 tBuOK 存在下，多种 3,4-二氢-2(1H)-喹唑啉酮以及 N-芳基化五元、六元和九元环脲在温和条件下很容易合成。该方法为环脲提供了一种替代合成工具包。

  DOI：

  10.1515/znb-2024-0045

文献信息

• <i>In Vitro</i> Optimization of EtNBS-PDT against Hypoxic Tumor Environments with a Tiered, High-Content, 3D Model Optical Screening Platform
  作者：Oliver J. Klein、Brijesh Bhayana、Yong Jin Park、Conor L. Evans

  DOI：10.1021/mp300262x

  日期：2012.11.5

  Hypoxia and acidosis are widely recognized as major contributors to the development of treatment resistant cancer. For patients with disseminated metastatic lesions, such as most women with ovarian cancer (OvCa), the progression to treatment resistant disease is almost always fatal. Numerous therapeutic approaches have been developed to eliminate treatment resistant carcinoma, including novel biologic, chemo, radiation, and photodynamic therapy (PDT) regimens. Recently, PDT using the cationic photosensitizer EtNBS was found to be highly effective against therapeutically unresponsive hypoxic and acidic OvCa cellular populations in vitro. To optimize this treatment regimen, we developed a tiered, high-content, image-based screening approach utilizing a biologically relevant OvCa 3D culture model to investigate a small library of side-chain modified EtNBS derivatives. The uptake, localization, and photocytotoxicity of these compounds on both the cellular and nodular levels were observed to be largely mediated by their respective ethyl side chain chemical alterations. In particular, EtNBS and its hydroxyl-terminated derivative (EtNBS-OH) were found to have similar pharmacological parameters, such as their nodular localization patterns and uptake kinetics. Interestingly, these two molecules were found to induce dramatically different therapeutic outcomes: EtNBS was found to be more effective in killing the hypoxic, nodule core cells with superior selectivity, while EtNBS-OH was observed to trigger widespread structural degradation of nodules. This breakdown of the tumor architecture can improve the therapeutic outcome and is known to synergistically enhance the antitumor effects of front-line chemotherapeutic regimens. These results, which would not have been predicted or observed using traditional monolayer or in vivo animal screening techniques, demonstrate the powerful capabilities of 3D in vitro screening approaches for the selection and optimization of therapeutic agents for the targeted destruction of specific cellular subpopulations.